Home › Athersys' MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation In Europe For Prevention Of Graft-Versus-Host Disease
 

Keywords :   


Athersys' MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation In Europe For Prevention Of Graft-Versus-Host Disease

2013-12-30 06:10:10| drugdiscoveryonline Home Page

Athersys, Inc. (Nasdaq:ATHX) announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has issued a positive opinion (EMA/OD/146/13) for the Company's allogeneic, multipotent adult progenitor cell, or MultiStem® therapy, for the prevention of graft-versus-host disease (GvHD)

Tags: europe cell drug disease

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
04.10Hurricane Kirk Graphics
04.10Hurricane Kirk Forecast Discussion Number 22
04.10Tropical Storm Leslie Forecast Discussion Number 10
04.10Hurricane Kirk Wind Speed Probabilities Number 22
04.10Hurricane Kirk Public Advisory Number 22
04.10Summary for Hurricane Kirk (AT2/AL122024)
04.10Tropical Storm Leslie Public Advisory Number 10
04.10Summary for Tropical Storm Leslie (AT3/AL132024)
More »